Rituximab

A booster dose of both vector and mRNA vaccine products yielded improved immune response in immunosuppressed patients using rituximab who had previously failed to show a response to the first two vaccines, according to data presented here.

Dimethyl fumarate and fingolimod appeared to have no significant difference in relapse rates, and rituximab appeared to have better relapse outcomes than natalizumab in patients with MS, according to results published in JAMA Network Open.

In this video, Dana DiRenzo, MD, MHS, instructor of medicine at Johns Hopkins, discussed a session on the new ACR recommendations for managing patients with rheumatoid arthritis.

In an extension of the REDO trial, most patients with rheumatoid arthritis on ultra-low-dose rituximab — either 200 or 500 mg — maintained low disease activity for up to 4 years, according to data presented at ACR Convergence 2021.

Treatment for thyroid eye disease should be personalized, with joint input from endocrinologists and ophthalmologists, according to two speakers.

First-line treatment of thyroid eye disease differs around the globe, with teprotumumab the most commonly prescribed treatment in North America and IV steroids most common in Europe, according to a speaker.

Early and short-term rituximab may be an option to treat patients with certain forms of autoimmune encephalitis, according to study results published in Neurology: Neuroimmunology & Neuroinflammation.

Rituximab and ocrelizumab appeared to increase risk for adverse outcomes among patients with MS and COVID-19, according to study results published in Neurology.

Rheumatologists opt for therapy regimens that include rituximab more often than nephrologists in treating refractory lupus nephritis or renal flare in children, according to data published in Pediatric Rheumatology.

There is no increased risk for cancer overall associated with the long-term use of TNF inhibitors for rheumatoid arthritis, according to data published in Rheumatology.